All the news Showing 3 of 163 articles from: Protease inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources US approval for hepatitis C drug telaprevir Keith Alcorn / 23 May 2011 The US Food and Drug Administration has approved a new hepatitis C drug telaprevir (Incivek), the agency announced today. Telaprevir is a direct-acting antiviral drug (an HCV protease inhibitor), licensed for use in combination ... European approval recommended for hepatitis C drug boceprevir Keith Alcorn / 23 May 2011 The European Medicines Agency has recommended marketing approval for Merck’s hepatitis C protease inhibitor boceprevir (Victrelis), the agency announced on May 20th. Boceprevir is the first direct-acting antiviral agent for hepatitis C to be ... Telaprevir works well for people with HIV/HCV co-infection Liz Highleyman / 02 March 2011 The experimental hepatitis C virus (HCV) protease inhibitor telaprevir, used with pegylated interferon plus ribavirin, produced good virological response in the first study of HIV/HCV co-infected individuals, according to interim data presented on Wednesday ... ← Prev1...1314151617Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive